Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Neuropharmacology

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neuropharm.2010.05.004PMID 20493887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced long‐term potentiation and impaired learning in phosphodiesterase 4D‐knockout (PDE4D−/−) mice

  2008cited by this paper
• The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.

  2008cited by this paper
• Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function.

  2008cited by this paper
• Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

  2008cited by this paper
• Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

  2008cited by this paper
• Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B)

  2008cited by this paper
• Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.

  2007cited by this paper
• Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes*

  2007cited by this paper
• Expression of the cGMP‐specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains

  2007cited by this paper
• Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

  2006cited by this paper
• Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

  2006cited by this paper
• Epac proteins: multi-purpose cAMP targets.

  2006cited by this paper
• Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species

  2006cited by this paper
• Membrane guanylyl cyclase receptors: an update.

  2006cited by this paper
• Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice.

  2006cited by this paper
• NO-sensitive guanylyl cyclase and NO-induced feedback inhibition in cGMP signaling.

  2005cited by this paper
• Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain.

  2005cited by this paper
• Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression.

  2004cited by this paper
• Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.

  2004cited by this paper
• BLAST: at the core of a powerful and diverse set of sequence analysis tools

  2004cited by this paper
• Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene.

  2003cited by this paper
• Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion.

  2003cited by this paper
• Immunohistochemical localization of PDE10A in the rat brain.

  2003cited by this paper
• Mfold web server for nucleic acid folding and hybridization prediction

  2003cited by this paper
• Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization.

  2003cited by this paper
• Cyclic nucleotide-gated ion channels.

  2002cited by this paper
• HugeIndex: a database with visualization tools for high-density oligonucleotide array data from normal human tissues

  2002cited by this paper
• Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning

  2002cited by this paper
• Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants.

  2002cited by this paper
• Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

  2002cited by this paper
• Regulation and role of adenylyl cyclase isoforms.

  2001cited by this paper
• Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain.

  2000cited by this paper
• Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)*

  1999cited by this paper
• Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP.

  1999cited by this paper
• Differential Expression of the Cyclic GMP-stimulated Phosphodiesterase PDE2A in Human Venous and Capillary Endothelial Cells

  1999cited by this paper
• Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase.

  1999cited by this paper
• CD3- and CD28-dependent induction of PDE7 required for T cell activation.

  1999cited by this paper
• Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action.

  1999cited by this paper
• Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence

  1998cited by this paper
• Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase.

  1998cited by this paper
• Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase*

  1998cited by this paper
• Differential cellular pattern of gene expression for two distinct cGMP-inhibited cyclic nucleotide phosphodiesterases in developing and mature rat brain.

  1996cited by this paper
• Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3′,5′-Cyclic Nucleotide Phosphodiesterases (*)

  1996cited by this paper
• High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells.

  1991cited by this paper
• A smaller molecular weight retinol binding protein in rat testis seminiferous tubules.

  1974cited by this paper

• Targeting phosphodiesterase 10A disrupts MAPK signaling pathways in the tumor microenvironment to unleash antitumor immunity

  2026cites this paper
• Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4.

  2026cites this paper
• Pharmacological characterization and preclinical evaluation of 11h: a novel, brain-penetrant PDE4 inhibitor for neurological disorders

  2026cites this paper
• PDE1B and PDE10A as novel targets for schizophrenia: from molecular design and synthesis to therapeutic promise

  2026cites this paper
• Roflumilast Elicits Therapeutic and Neuroprotective Effects in 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Neurodegeneration in Rats by Mitigating NLRP3 Inflammasome-Mediated Pyroptosis, Ferroptosis, and Glial Activation

  2026cites this paper
• Phosphodiesterase 1A overexpression contributes to the progression of renal fibrosis.

  2025cites this paper
• Erectile Dysfunction Drugs as Potential Therapy for Cognitive Decline: Preclinical and Translational Evidence

  2025cites this paper
• Steady-state neuron-predominant LINE-1 encoded ORF1p protein and LINE-1 RNA increase with aging in the mouse and human brain

  2025cites this paper
• Phosphodiesterase-4 Inhibition as a Potential Therapeutic Strategy in the Management of Obesity: a Review.

  2025cites this paper
• Phosphodiesterase 4 inhibition as a novel treatment for stroke

  2025cites this paper
• Phosphodiesterase type 1 regulates adenosine 2A receptor-associated cAMP signaling at the plasma membrane to increase myocardial contractility

  2025cites this paper
• 5‐hydroxymethylcytosine features of portal venous blood predict metachronous liver metastases of colorectal cancer and reveal phosphodiesterase 4 as a therapeutic target

  2025cites this paper
• Roflumilast attenuates doxorubicin and cyclophosphamide combination-induced chemobrain in rats through modulation of NLRP3/ASC/caspase-1/GSDMD axis.

  2025cites this paper
• Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions

  2025influential citation
• Discovery of Effective Inhibitors Against Phosphodiesterase 9, a Potential Therapeutic Target of Alzheimer’s Disease with Antioxidant Capacities

  2025cites this paper
• Phosphodiesterase 7 inhibition reduces L-DOPA-induced dyskinesias in parkinsonian nonhuman primates.

  2025cites this paper
• Radiation dosimetry of [11C]TZ1964B as determined by whole-body PET imaging of nonhuman primates

  2025cites this paper
• Development of a Novel 18F-Labeled Radioligand for Imaging Phosphodiesterase 7 with Positron Emission Tomography

  2025cites this paper
• Phosphodiesterase Inhibition Increases Striatal GDNF and Protects Against Preclinical Parkinsonism

  2025cites this paper
• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B

  2025cites this paper
• Radiosynthesis and Preclinical Evaluation of a Novel 11C‑Labeled Pyrazolopyrimidine Derivative for Positron Emission Tomography Imaging of Phosphodiesterase 2A.

  2025cites this paper
• Exploring dual inhibitors Carbonic Anhydrases and Phosphodiesterase 5 as potential agents for treatment Alzheimer's disease.

  2025cites this paper
• [11C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B

  2025cites this paper
• Discovery of novel pyrrolopyrimidine-based PDE7 inhibitors against alcoholic liver injury

  2025cites this paper
• Combining vinpocetine or cocoa with levodopa, Coenzyme Q10 and vitamin B complex mitigates rotenone-induced Parkinson's disease in rats: Impact on Nrf2/HO-1, NF-kB, AMPK/SIRT-1/Beclin-1, AKT/GSK-3β/CREB/BDNF and Apoptotic Pathways.

  2025cites this paper
• E2027 (irsenontrine), a phosphodiesterase 9 inhibitor, enhances cholinergic function when combined with donepezil hydrochloride.

  2025cites this paper
• Mechanistic insights into the identification of Phosphodiesterase 2 inhibitors from acridine analogues

  2025cites this paper
• Activation of PDE2A moderates pathologically high cAMP/PKA responses to dopamine in dyskinetic mice.

  2025cites this paper
• Protein Kinase A Signaling in Cortisol Production and Adrenal Cushing’s Syndrome

  2025cites this paper
• Phosphodiesterase 2A as a Therapeutic Target for Relieving Mechanical Allodynia and Modulating Microglial Polarization in Neuropathic Pain Models Following Spinal Cord Injury.

  2025cites this paper
• A novel selective phosphodiesterase 9 inhibitor, irsenontrine (E2027), enhances GluA1 phosphorylation in neurons and improves learning and memory via cyclic GMP elevation.

  2025cites this paper
• PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges

  2025influential citation
• Altered Expression of PDE4 Genes in Schizophrenia: Insights from a Brain and Blood Sample Meta-Analysis and iPSC-Derived Neurons

  2024cites this paper
• The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models

  2024cites this paper
• Effects of the Phosphodiesterase 10A Inhibitor MR1916 on Alcohol Self-Administration and Striatal Gene Expression in Post-Chronic Intermittent Ethanol-Exposed Rats

  2024cites this paper
• PDE4 inhibitors: potential protective effects in inflammation and vascular diseases

  2024cites this paper
• Intertwined regulators: hypoxia pathway proteins, microRNAs, and phosphodiesterases in the control of steroidogenesis

  2024cites this paper
• The multidrug resistance protein (MRP) 4 is expressed and functionally active in isolated bladder from pig.

  2024cites this paper
• Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma

  2024cites this paper
• Inflammation in cerebral ischemia reperfusion improved by avanafil via nod-like receptor protein-3 inflammasome: an experimental study in rats

  2024cites this paper
• Preclinical Evaluation of MK-8189: A Novel Phosphodiesterase 10A Inhibitor for the Treatment of Schizophrenia.

  2024cites this paper
• Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases

  2024cites this paper
• Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases.

  2024cites this paper
• Discovery and Optimization of Dihydroquinolin-2(1H)-ones as Novel Highly Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.

  2024cites this paper
• In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia

  2024cites this paper
• Phosphodiesterase inhibition and Gucy2C activation enhance tyrosine hydroxylase Ser40 phosphorylation and improve 6-hydroxydopamine-induced motor deficits

  2024cites this paper
• Development of a Candidate 11C‑Labeled Selective Phosphodiesterase 1 Radioligand for Positron Emission Tomography

  2024cites this paper
• Reference Genes for the Real-Time PCR Analysis of Relative Gene Expression in Various Human Myocardial Pathologies

  2024cites this paper
• Beyond traditional pharmacology: evaluating phosphodiesterase inhibitors in autism spectrum disorder

  2024cites this paper
• THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia.

  2024cites this paper
• Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated Gα in Human Cancer

  2024cites this paper
• Cerebral blood flow and cognition after 3 months tadalafil treatment in small vessel disease (ETLAS-2): study protocol for a randomized controlled trial

  2024cites this paper
• A Novel PDE10A Inhibitor for Tourette Syndrome and Other Movement Disorders

  2024cites this paper
• Roflumilast-loaded nanostructured lipid carriers attenuate oxidative stress and neuroinflammation in Parkinson’s disease model

  2024cites this paper
• Ca2+-dependent phosphodiesterase 1 regulates the plasticity of striatal spiny projection neuron glutamatergic synapses

  2024cites this paper
• Roflumilast and cognition enhancement: A translational perspective.

  2024cites this paper
• Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)

  2024cites this paper
• 磷酸二酯酶4抑制剂在中枢神经系统疾病中的作用研究进展

  2024cites this paper
• Genome-wide association studies (GWAS) and post-GWAS analyses of impulsivity: A systematic review.

  2024cites this paper
• Longevity, enhanced memory, and altered density of dendritic spines in hippocampal CA3 and dentate gyrus after hemizygous deletion of Pde2a in mice

  2024cites this paper
• The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)

  2024cites this paper
• Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential

  2023cites this paper
• Designing of 2,3-dihydrobenzofuran derivatives as inhibitors of PDE1B using pharmacophore screening, ensemble docking and molecular dynamics approach

  2023cites this paper
• Selective PDE4B and PDE4D inhibitors produce distinct behavioral responses to ethanol and GABAergic drugs in mice.

  2023cites this paper
• Network pharmacology and molecular docking prediction, combined with experimental validation to explore the potential mechanism of Qishen Yiqi pills against HF-related cognitive dysfunction.

  2023cites this paper
• Phosphodiesterase inhibitors in psychiatric disorders

  2023cites this paper
• PDE10A Mutation as an Emerging Cause of Childhood-Onset Hyperkinetic Movement Disorders: A Review of All Published Cases

  2023cites this paper
• Advances in the development of phosphodiesterase 7 inhibitors.

  2023cites this paper
• Adenosinergic Pathway in Parkinson’s Disease: Recent Advances and Therapeutic Perspective

  2023cites this paper
• Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia

  2023influential citation
• Defects in AMPAR trafficking and microglia activation underlie socio-cognitive deficits associated to decreased expression of Phosphodiesterase 2A

  2023cites this paper
• Testing the cognitive effects of tadalafil. Neuropsychological secondary outcomes from the PASTIS trial

  2023cites this paper
• Cross-pathway integration of cAMP signals through cGMP and calcium-regulated phosphodiesterases in mouse striatal cholinergic interneurons

  2023cites this paper
• Beyond the heart - Exploring the therapeutic potential of PDE3 inhibitors

  2023cites this paper
• Phosphodiesterase in heart and vessels: from physiology to diseases

  2023cites this paper
• Phosphodiesterase and psychiatric disorders: a two-sample Mendelian randomization study

  2023cites this paper
• Deciphering the Role of Peroxisome Proliferator-activated Receptor α and Phosphodiesterase Type 5 Targets in Alzheimer's Disease.

  2023cites this paper
• Inhibition of phosphodiesterase PDE8B reduces activation of primordial follicles in mouse ovaries

  2023cites this paper
• An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential.

  2023cites this paper
• Structural Insights into the lead identification of sub-type selective PDE4B Inhibitors from plant bioactive molecule analogues

  2023cites this paper
• PDE5 inhibitor drugs for use in dementia

  2023cites this paper
• Advances in targeting Phosphodiesterase 1: From mechanisms to potential therapeutics.

  2023cites this paper
• Tolerance to paradoxical increase in motor activity caused by inhibition of phosphodiesterase 10a in a model of hypodopaminergy

  2023cites this paper
• Blood–Brain Barrier Rescue by Roflumilast After Transient Global Cerebral Ischemia in Rats

  2023cites this paper
• Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.

  2022cites this paper
• A novel phosphodiesterase 9A inhibitor LW33 protects against ischemic stroke through the cGMP/PKG/CREB pathway.

  2022cites this paper
• Phosphodiesterase 2A inhibition corrects the aberrant behavioral traits observed in genetic and environmental preclinical models of Autism Spectrum Disorder

  2022cites this paper
• Protective effects of phosphodiesterase 2 inhibitor against Aβ1-42 induced neuronal toxicity.

  2022cites this paper
• Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia

  2022cites this paper
• Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.

  2022cites this paper
• Endoplasmic reticulum stress mediates homocysteine-induced hypertrophy of cardiac cells through activation of cyclic nucleotide phosphodiesterase 1C

  2022cites this paper
• E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies

  2022cites this paper
• Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice

  2022cites this paper
• Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson’s Disease Therapy

  2022cites this paper
• Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.

  2022cites this paper
• Evaluation of the acute oral toxicity and antipsychotic activity of a dual inhibitor of PDE1B and PDE10A in rat model of schizophrenia

  2022cites this paper
• BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor

  2022cites this paper
• Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)

  2022cites this paper
• PDE3 inhibition by cilostazol attenuated developmental hyperserotonemia induced behavioural and biochemical deficits in a rat model of autism spectrum disorder

  2022cites this paper